Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease.  Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases.  Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics. 

Biotechnology

Volastra

Charles Hugh-Jones

Jacqueline Gonzalez

Scott Drutman

Rachel Zolot Schwartz

Joseph Avallone

Jianmin Mao

Michael Su

The Leadership Team at Volastra Therapeutics is responsible for steering the company's strategic direction and overseeing research initiatives to develop novel therapies targeting metastatic disease. Comprising top executives with expertise in science and business, the team drives innovation, aligns research goals with corporate strategy, and ensures the successful translation of groundbreaking scientific findings into effective treatments for patients.

Leadership Team

Advisory Team

Scientific Research Team

Leadership Team

About

Team members

Other teams at Volastra

Advisory Team

Scientific Research Team